JP4842139B2 - 皮膚瘢痕の縮小 - Google Patents

皮膚瘢痕の縮小 Download PDF

Info

Publication number
JP4842139B2
JP4842139B2 JP2006541731A JP2006541731A JP4842139B2 JP 4842139 B2 JP4842139 B2 JP 4842139B2 JP 2006541731 A JP2006541731 A JP 2006541731A JP 2006541731 A JP2006541731 A JP 2006541731A JP 4842139 B2 JP4842139 B2 JP 4842139B2
Authority
JP
Japan
Prior art keywords
composition
rad
cip1
waf1
wound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006541731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007512377A (ja
JP2007512377A5 (enExample
Inventor
ダンリング グウ，
モニカ ゼペダ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canji Inc
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of JP2007512377A publication Critical patent/JP2007512377A/ja
Publication of JP2007512377A5 publication Critical patent/JP2007512377A5/ja
Application granted granted Critical
Publication of JP4842139B2 publication Critical patent/JP4842139B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2006541731A 2003-11-24 2004-11-23 皮膚瘢痕の縮小 Expired - Fee Related JP4842139B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52499303P 2003-11-24 2003-11-24
US60/524,993 2003-11-24
PCT/US2004/039633 WO2005051971A1 (en) 2003-11-24 2004-11-23 Reduction of dermal scarring

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011160099A Division JP2011207912A (ja) 2003-11-24 2011-07-21 皮膚瘢痕の縮小

Publications (3)

Publication Number Publication Date
JP2007512377A JP2007512377A (ja) 2007-05-17
JP2007512377A5 JP2007512377A5 (enExample) 2007-12-27
JP4842139B2 true JP4842139B2 (ja) 2011-12-21

Family

ID=34632948

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006541731A Expired - Fee Related JP4842139B2 (ja) 2003-11-24 2004-11-23 皮膚瘢痕の縮小
JP2011160099A Withdrawn JP2011207912A (ja) 2003-11-24 2011-07-21 皮膚瘢痕の縮小

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011160099A Withdrawn JP2011207912A (ja) 2003-11-24 2011-07-21 皮膚瘢痕の縮小

Country Status (13)

Country Link
US (3) US7465442B2 (enExample)
EP (1) EP1692154A4 (enExample)
JP (2) JP4842139B2 (enExample)
KR (1) KR101167330B1 (enExample)
CN (2) CN100482674C (enExample)
AU (1) AU2004293474B2 (enExample)
BR (1) BRPI0416920A (enExample)
CA (1) CA2546287C (enExample)
IL (1) IL175603A (enExample)
NO (1) NO20062978L (enExample)
NZ (1) NZ546983A (enExample)
WO (1) WO2005051971A1 (enExample)
ZA (1) ZA200604147B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100482674C (zh) * 2003-11-24 2009-04-29 坎吉有限公司 皮肤瘢痕形成的减少
AU2009205429A1 (en) 2008-01-14 2009-07-23 Conventus Orthopaedics Inc. Apparatus and methods for fracture repair
US8796443B2 (en) 2008-09-22 2014-08-05 Rxi Pharmaceuticals Corporation Reduced size self-delivering RNAi compounds
EP2523614A4 (en) 2010-01-15 2017-02-15 Conventus Orthopaedics, Inc. Rotary-rigid orthopaedic rod
CN105534561B (zh) 2010-01-20 2018-04-03 康文图斯整形外科公司 用于骨接近和骨腔准备的装置及方法
JP2013521880A (ja) 2010-03-08 2013-06-13 コンベンタス オーソピディックス， インコーポレイテッド 骨インプラントを固定するための装置および方法
KR20180044433A (ko) 2010-03-24 2018-05-02 알엑스아이 파마슈티칼스 코포레이션 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
EP3077050B1 (en) * 2013-12-04 2020-10-21 Phio Pharmaceuticals Corp. Methods for treatment of wound healing utilizing chemically modified oligonucleotides
AU2014362251B2 (en) 2013-12-12 2019-10-10 Conventus Orthopaedics, Inc. Tissue displacement tools and methods
US10900039B2 (en) 2014-09-05 2021-01-26 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
SG11201808704YA (en) 2016-04-14 2018-11-29 Trizell Ltd Viral vector stabilization
WO2019010252A2 (en) 2017-07-04 2019-01-10 Conventus Orthopaedics, Inc. Apparatus and methods for treatment of a bone

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6289629A (ja) * 1985-06-21 1987-04-24 Nitta Zerachin Kk 組織親和性コラ−ゲンとその製法
WO2000041647A1 (en) * 1999-01-19 2000-07-20 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4505266A (en) 1981-10-26 1985-03-19 Massachusetts Institute Of Technology Method of using a fibrous lattice
US4485097A (en) 1982-05-26 1984-11-27 Massachusetts Institute Of Technology Bone-equivalent and method for preparation thereof
WO1992002247A1 (en) * 1990-08-01 1992-02-20 Chiron Ophthalmics, Inc. Method for treating corneal endothelial wounds
US5302706A (en) 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
US6372249B1 (en) 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5596079A (en) 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
KR100331363B1 (ko) 1992-10-16 2002-12-05 콜드 스프링 하버 래보레이토리 사이클린복합체재배열및그것과관련된용도
US6211334B1 (en) 1992-10-16 2001-04-03 Cold Spring Harbor Cell-cycle regulatory proteins, and uses related thereto
FR2702152B1 (fr) 1993-03-03 1995-05-24 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.
CA2170641C (en) 1993-08-30 2011-11-15 James R. Smith Senescent cell-derived inhibitors of dna synthesis
TW442569B (en) 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
EP0702730A4 (en) 1994-03-18 1997-05-07 Univ Utah Res Found COREWAY MUTTATIONS IN THE MTS GENE AND METHODS FOR DETECTING AN APPROXIMATION OF CANCER IN THE MTS GENE
ATE283355T1 (de) 1994-05-24 2004-12-15 Baylor College Medicine Mimetika von aus alternden zellen abgeleitete hemmer der dna synthese
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
WO1996012506A1 (en) 1994-10-24 1996-05-02 Baylor College Of Medecine Senescent cell-derived inhibitors of dna synthesis
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
AU4602396A (en) 1994-12-22 1996-07-10 Regents Of The University Of Michigan, The Dna encoding a 20 kd cdk6 inhibiting protein
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5856094A (en) 1995-05-12 1999-01-05 The Johns Hopkins University School Of Medicine Method of detection of neoplastic cells
US6027742A (en) 1995-05-19 2000-02-22 Etex Corporation Bioresorbable ceramic composites
US5756283A (en) 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
HUP9901908A3 (en) 1995-07-17 2000-02-28 Univ Texas P16 expression constructs and their application in cancer therapy
GB9519275D0 (en) 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US6001853A (en) * 1996-01-26 1999-12-14 The United States Of America As Represented By The Department Of Health And Human Services Hydroxylamine compositions for the prevention or retardation of cataracts
AU726584B2 (en) 1996-04-10 2000-11-09 University Of Southern California Gene therapy for proliferative vitreoretinopathy
IT1285790B1 (it) * 1996-09-24 1998-06-24 Angeletti P Ist Richerche Bio Adenovirus difettivi ricombinanti che codificano per mutanti di interleuchina 6 umana (hil-6) con attivita' antagonista o
US6274614B1 (en) 1997-02-11 2001-08-14 Qlt Inc. Methods, compositions and articles for reducing or preventing the effects of inflammation
JPH11205102A (ja) 1998-01-13 1999-07-30 Mitsubishi Electric Corp 遅延同期回路
US6489305B1 (en) 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
AU6919300A (en) * 1999-08-20 2001-03-19 University Of Pittsburgh Methods for in vivo gene delivery to sites of cartilage damage
US6579522B1 (en) * 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
US6667173B2 (en) 2000-12-01 2003-12-23 The Schepens Eye Research Institute Nucleic acids encoding platelet derived growth factor-alpha receptors
CN100482674C (zh) * 2003-11-24 2009-04-29 坎吉有限公司 皮肤瘢痕形成的减少
US7947267B2 (en) * 2004-10-08 2011-05-24 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6289629A (ja) * 1985-06-21 1987-04-24 Nitta Zerachin Kk 組織親和性コラ−ゲンとその製法
WO2000041647A1 (en) * 1999-01-19 2000-07-20 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents

Also Published As

Publication number Publication date
KR20060127414A (ko) 2006-12-12
IL175603A (en) 2011-02-28
NZ546983A (en) 2009-05-31
EP1692154A4 (en) 2009-07-08
CN101507822B (zh) 2012-06-06
JP2007512377A (ja) 2007-05-17
AU2004293474A1 (en) 2005-06-09
ZA200604147B (en) 2007-11-28
US7465442B2 (en) 2008-12-16
WO2005051971A1 (en) 2005-06-09
US20090142397A1 (en) 2009-06-04
NO20062978L (no) 2006-06-26
AU2004293474B2 (en) 2010-12-23
CN101507822A (zh) 2009-08-19
US20050271623A1 (en) 2005-12-08
US20110129534A1 (en) 2011-06-02
CN100482674C (zh) 2009-04-29
US8329671B2 (en) 2012-12-11
BRPI0416920A (pt) 2007-01-23
JP2011207912A (ja) 2011-10-20
EP1692154A1 (en) 2006-08-23
CA2546287C (en) 2014-04-22
KR101167330B1 (ko) 2012-07-23
CA2546287A1 (en) 2005-06-09
CN1906205A (zh) 2007-01-31
IL175603A0 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
US8329671B2 (en) Reduction of dermal scarring
US20020076395A1 (en) Modified adipose tissue and related implants and methods
JP2011148834A (ja) インターフェロン耐性腫瘍の処置のための方法および組成物
CZ288790B6 (cs) Rekombinantní adenovirus, jeho použití a farmaceutický přípravek
US20110044947A1 (en) Methods of treating cardiac disorders
US6489305B1 (en) Methods and compositions for the treatment of ocular diseases
US20160144055A1 (en) Gene therapy vector for treatment of steroid glaucoma
EP0948520B1 (en) Tissue specific expression of retinoblastoma protein
WO1998021228A9 (en) Tissue specific expression of retinoblastoma protein
MXPA06005826A (en) Reduction of dermal scarring
WO1996015245A1 (en) A process of inhibiting non-neoplastic pathological cell proliferation
CN100502942C (zh) 肝细胞生长因子在预防或治疗组织粘连中的应用
IL129922A (en) A unique form of expression for retinoblastoma protein tissue
HK1019751B (en) Tissue specific expression of retinoblastoma protein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110721

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110920

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111005

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141014

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees